title: Topical dexamethasone and tympanic membrane perforation healing in otitis media: a short-term study.
abstract: BACKGROUND
  The safety and efficacy of topical corticosteroids have not been established in the treatment of acute otitis media (AOM) with tympanic membrane (TM) perforation. Specific concerns include the risk for nonhealing TM perforations. Previous studies have not been done in models with concurrent AOM. The purpose of this study was to determine whether the addition of dexamethasone to topical ciprofloxacin affects healing of AOM-related TM perforations.
  
  
  METHODS
  Bilateral AOM was induced in chinchillas by transbulla injection of Streptococcus pneumoniae, and TMs were perforated with a CO2 laser 3 to 5 days later. Each animal received ciprofloxacin-dexamethasone in one ear and ciprofloxacin in the other, twice daily for 7 days. Tympanic membranes were assessed for 4 weeks.
  
  
  RESULTS
  Fifteen of 55 ciprofloxacin-treated and 37 of 55 ciprofloxacin-dexamethasone-treated TMs failed to heal within the 4-week study period (p < 0.001). Exposure to dexamethasone increased the odds for persistent perforation by 5.5 (95% confidence interval, 2.4-12.6). At 4 weeks, mean TM perforation diameter was 0.9 mm in ciprofloxacin-treated ears and 2.1 mm in ciprofloxacin-dexamethasone-treated ears (p < 0.001).
  
  
  CONCLUSIONS
  Topical dexamethasone hinders TM healing in a chinchilla model of AOM at short-term follow-up. Longer follow-up is needed.
authors.affiliation: Department of Otolaryngology, University of Florida, 1600 SW Archer Rd., Gainesville, FL 32610-0264, U.S.A. Patrick.Antonelli@ent.ufl.edu
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Antonelli
authors.forename: Almut G
authors.initials: AG
authors.lastname: Winterstein
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Schultz
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002682:Chinchilla; D002939:Ciprofloxacin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005938:Glucocorticoids; D008297:Male; D010033:Otitis Media / Q000188:drug therapy*; D011008:Pneumococcal Infections / Q000188:drug therapy; D012044:Regression Analysis; D016896:Treatment Outcome; D014432:Tympanic Membrane / Q000187:drug effects*; D018058:Tympanic Membrane Perforation / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000890:Anti-Infective Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D002939:Ciprofloxacin; D003907:Dexamethasone